Caszyme and industry partners unveiled Cas12l nucleases, a family of compact CRISPR enzymes (~850 amino acids) reported to deliver high editing efficiency with different PAM requirements and staggered DNA breaks. Companies using Cas12l emphasize improved deliverability for in vivo and ex vivo therapeutic approaches and claim editing efficiencies that can exceed legacy Cas proteins in certain contexts. The availability of new, smaller nucleases expands options for therapeutic developers facing delivery constraints and licensing bottlenecks associated with widely used Cas enzymes. The market will monitor comparative off‑target profiles, immunogenicity, delivery compatibility, and licensing terms as teams decide whether to integrate Cas12l into clinical gene‑editing platforms.